Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease

References

• Bach JP, Riedel O, Klotsche J, et al. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson’s disease. J Neurol Sci. 2012;314:41–47.
   PubMed Web of Science ®Google Scholar
• De Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology. 2000;54:S21–S23.
   PubMed Web of Science ®Google Scholar
• Rajput AH, Birdi S. Epidemiology of Parkinson’s disease. Parkinsonism Relat Disord. 1997;3:175–186.
   PubMedGoogle Scholar
• Weiner WJ. There is no Parkinson disease. Arch Neurol. 2008;65:705–708.
   PubMed Web of Science ®Google Scholar
• Berg D, Godau J, Seppi K, et al. The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol. 2013;20:102–108.
   PubMed Web of Science ®Google Scholar
• Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson’s disease: conceptual aspects. J Neural Transm. 2004;111:201–216.
   PubMed Web of Science ®Google Scholar
• Weiner WJ. What do clinical trials tell us about treating patients. Parkinsonism Relat Disord. 2009;15:S34–S37.
   PubMed Web of Science ®Google Scholar
• Müller T. Drug therapy in patients with Parkinson’s disease. Transl Neurodegener. 2012;1:1–10.
   PubMedGoogle Scholar
• Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59:459–466.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol. 2003;54:403–414.
   PubMed Web of Science ®Google Scholar
• Riederer P, Gerlach M, Müller T, et al. Relating mode of action to clinical practice: dopaminergic agents in Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:466–479.
   PubMed Web of Science ®Google Scholar
• Lewitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63:295–302.
   PubMed Web of Science ®Google Scholar
• Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78:1096–1099.
   PubMed Web of Science ®Google Scholar
• Verhagen ML, Del DP, Van Den MP, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998;50:1323–1326.
   PubMed Web of Science ®Google Scholar
• Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999;56:1383–1386.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Tanner CM, Hauser RA, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord. 2015;30:788–795.
   PubMed Web of Science ®Google Scholar
• Gregoire L, Jourdain VA, Townsend M, et al. Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord. 2013;19:508–514.
   PubMed Web of Science ®Google Scholar
• Podurgiel S, Collins-Praino LE, Yohn S, et al. Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. Pharmacol Biochem Behav. 2013;105:105–111.
   PubMed Web of Science ®Google Scholar
• Marzo A, Bo L D, Monti NC, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004;50:77–85.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Safinamide: first global approval. Drugs. 2015;75:705–711.
   PubMed Web of Science ®Google Scholar
• Krosser S, Marquet A, Gallemann D, et al. Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects. Biopharm Drug Dispos. 2012;33:550–559.
   PubMed Web of Science ®Google Scholar
• Leuratti C, Sardina M, Ventura P, et al. Disposition and metabolism of safinamide, a novel drug for Parkinson’s disease, in healthy male volunteers. Pharmacology. 2013;92:207–216.
   PubMed Web of Science ®Google Scholar
• Seithel-Keuth A, Johne A, Freisleben A, et al. Absolute bioavailability and effect of food on the disposition of safinamide immediate release tablets in healthy adult subjects. Clin Pharmacol Drug Dev. 2013;2:79–89.
   PubMed Web of Science ®Google Scholar
• Fariello RG, McArthur RA, Bonsignori A, et al. Preclinical evaluation of PNU-151774E as a novel anticonvulsant. J Pharmacol Exp Ther. 1998;285:397–403.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Caccia C, Marzo A, et al. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol. 2003;26:213–217.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2016;74(2):216–224.
   Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29:229–237.
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014;29:1273–1280.
   PubMed Web of Science ®Google Scholar
• Di Stefano AF, Rusca A. Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2011;384:505–515.
   PubMed Web of Science ®Google Scholar
• Müller T. The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson’s disease. Clin Med Insights: Ther. 2010;2:155–168.
   Google Scholar
• Müller T, Woitalla D, Saft C, et al. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord. 2000;6:171–173.
   PubMed Web of Science ®Google Scholar
• Loprete L, Leuratti C, Cattaneo C, et al. Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson’s disease. Pharmacol Res Perspect. 2016;4:e00251.
   PubMedGoogle Scholar
• Müller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75:157–174.
   PubMed Web of Science ®Google Scholar
• Jimenez-Jimenez FJ, Onso-Navarro H, Garcia-Martin E, et al. Advances in understanding genomic markers and pharmacogenetics of Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2016;12:433–448.
   PubMed Web of Science ®Google Scholar
• Schnitker J, Müller T. Meta-analysis of placebo-controlled clinical trials of safinamide and entacapone as add-on therapy to levodopa in the treatment of Parkinson’s disease. Eur Neurol Rev. 2015;10:15–22.
   Google Scholar
• Przuntek H, Conrad B, Dichgans J, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol. 1999;6:141–150.
   PubMed Web of Science ®Google Scholar
• Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine–results of a phase II double-blind study. Pharmacopsychiatry. 1988;21:144–146.
   PubMed Web of Science ®Google Scholar
• Comi G, Leocani L. Assessment, pathophysiology and treatment of fatigue in multiple sclerosis. Expert Rev Neurother. 2002;2:867–876.
   PubMedGoogle Scholar
• Riederer P, Müller T. Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin Drug Metab Toxicol. 2017;13:233–240.
   PubMed Web of Science ®Google Scholar
• Apud JA, Mattay V, Chen J, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007;32:1011–1020.
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, Kolsky AR, et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol. 1999;19:329–335.
   PubMed Web of Science ®Google Scholar
• Moreau JL, Borgulya J, Jenck F, et al. Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol. 1994;5:344–350.
   PubMed Web of Science ®Google Scholar
• Gasparini M, Fabrizio E, Bonifati V, et al. Cognitive improvement during Tolcapone treatment in Parkinson’s disease. J Neural Transm. 1997;104:887–894.
   PubMed Web of Science ®Google Scholar
• Kayser AS, Allen DC, Navarro-Cebrian A, et al. Dopamine, corticostriatal connectivity, and intertemporal choice. J Neurosci. 2012;32:9402–9409.
   PubMed Web of Science ®Google Scholar
• Roussos P, Giakoumaki SG, Bitsios P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biol Psychiatry. 2009;66:997–1004.
   PubMed Web of Science ®Google Scholar
• Petrov D, Pedros I, De Lemos ML, et al. Mavoglurant as a treatment for Parkinson’s disease. Expert Opin Investig Drugs. 2014;23:1165–1179.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord. 2013;28:1838–1846.
   PubMed Web of Science ®Google Scholar
• Müller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opin Pharmacother. 2006;7:1715–1730.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Ferla RL, Bonizzoni E, et al. Long-term effects of safinamide on dyskinesia in mid- to late-stage parkinson’s disease: a post-hoc analysis. J Parkinsons Dis. 2015;5:475–481.
   PubMedGoogle Scholar
• Cattaneo C, Barone P, Bonizzoni E, et al. Effects of safinamide on pain in fluctuating parkinson’s disease patients: a post-hoc analysis. J Parkinsons Dis. 2017;7:95–101.
   PubMedGoogle Scholar
• Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64:208–214.
   PubMed Web of Science ®Google Scholar
• Magyar K. The pharmacology of selegiline. Int Rev Neurobiol. 2011;100:65–84.
   PubMed Web of Science ®Google Scholar
• Müller T, Hoffmann JA, Dimpfel W, et al. Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J Neural Transm. 2013;120:761–765.
   PubMed Web of Science ®Google Scholar
• Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63:228–234.
   PubMed Web of Science ®Google Scholar
• Barone P, Santangelo G, Morgante L, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Eur J Neurol. 2015;22:1184–1191.
   PubMed Web of Science ®Google Scholar
• Hoy SM, Keating GM. Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. Drugs. 2012;72:643–669.
   PubMed Web of Science ®Google Scholar